 Recurrent metastatic head neck squamous cell carcinoma clinical univariate multivariate analysis response survival cisplatin-based chemotherapy patients recurrent and/or metastatic head neck squamous cell cancer consecutive phase II trials cisplatinum C-DDP combinations C-DDP bleomycin fluorouracil CFB patients cisplatinum vindesin patients CV CFB combination C-DDP continuous infusion hours patients day patients CV regimen different schedules VDS weekly patients continuous infusion patients following variables sex age performance status previous therapy local recurrence length disease-free interval DFI distant metastases weight loss primary site histological differentiation type chemotherapy previous chemotherapy evaluable/measurable disease erythrosedimentation rate relation response chemotherapy WHO survival univariate multivariate analysis Cox Overall response rate RR CR PR CFB protocols RR NS CV combination group different combinations RR CFB C-DDPci CFB C-DDP hour CV VDS CV VDSci patient populations different combination metastatic patients Univariate analysis multiple variables age years previous therapy absence local relapse metastatic disease DFI measurable disease significant probability response Median survival months patients months nonresponders months responders univariate analysis significant factors survival weight loss long DFI response erythrosedimentation rate ESR hr presence bone metastasis number metastases Multivariate analysis shows PS absence local relapse disease-free interval significant prognostic factors response Multivariate analysis factors significance survival PS weight loss response analysis clinical pattern evolution RR local recurrent disease untreated patients metastatic disease presentation ABSTRACT TRUNCATED AT WORDS